Abstract
Transarterial chemoembolization (TACE) is a well-recognized therapy for patients with unresectable hepatocellular carcinoma (HCC). However, the long-term efficacy of TACE remains unsatisfactory. TACE initiates angiogenesis in the residual viable tumor as a result of hypoxia generated by the procedure. Accordingly, the combination of TACE with anti-angiogenic agent might represent an effective strategy to improve outcomes. Apatinib, a highly potent small molecule anti-angiogenic agent, has been proved to improve overall survival (OS) in patients with pretreated advanced HCC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call